Patient Characteristics
| Sex | |
| Male | 102 (51%) |
| Female | 99 (49%) |
| Median age | 29 years (range, 1 to 51) |
| Median leukocyte count at pre sentation (109/L) | 5.1 (range, 0.2 to 300) |
| FAB subtypes | |
| M1 | 21 |
| M2 | 46 |
| M3 | 26 (M1-3: 46%) |
| M4 | 43 |
| M5 | 14 |
| M6 | 11 |
| M7 | 1 (M4-7: 34%) |
| Unknown | 39 (19%) |
| Median remission-transplant interval (weeks) | 16 (range, 1 to 96) |
| Conditioning regimen | |
| Melphalan-TBI | 114 (57%) |
| Cyclophosphamide-TBI | 70 (35%) |
| Chemotherapy only | 17 (8%) |
| GVHD prophylaxis | |
| Cyclosporine alone | 136 (68%) |
| Cyclosporine-methotrexate | 53 (26%) |
| T-cell depletion | 12 (6%) |
| Blood group match | 127 (63%) |
| Blood group mismatch | 74 (37%) |
| Median nucleated cell dose (108/kg) | 2.42 (range, 1.02 to 9.72) |
| Any grade acute or chronic GVHD | 173 (86%) |
| No GVHD | 28 (14%) |
| Median absolute lymphocytes on day 29 (109/L) | 0.49 (range, 0 to 5.87)* |
| Outcome | |
| Alive | 86 (43%)-151 |
| Relapse | 25 (12%)-151 |
| Toxic deaths | 92 (46%) |
| Sex | |
| Male | 102 (51%) |
| Female | 99 (49%) |
| Median age | 29 years (range, 1 to 51) |
| Median leukocyte count at pre sentation (109/L) | 5.1 (range, 0.2 to 300) |
| FAB subtypes | |
| M1 | 21 |
| M2 | 46 |
| M3 | 26 (M1-3: 46%) |
| M4 | 43 |
| M5 | 14 |
| M6 | 11 |
| M7 | 1 (M4-7: 34%) |
| Unknown | 39 (19%) |
| Median remission-transplant interval (weeks) | 16 (range, 1 to 96) |
| Conditioning regimen | |
| Melphalan-TBI | 114 (57%) |
| Cyclophosphamide-TBI | 70 (35%) |
| Chemotherapy only | 17 (8%) |
| GVHD prophylaxis | |
| Cyclosporine alone | 136 (68%) |
| Cyclosporine-methotrexate | 53 (26%) |
| T-cell depletion | 12 (6%) |
| Blood group match | 127 (63%) |
| Blood group mismatch | 74 (37%) |
| Median nucleated cell dose (108/kg) | 2.42 (range, 1.02 to 9.72) |
| Any grade acute or chronic GVHD | 173 (86%) |
| No GVHD | 28 (14%) |
| Median absolute lymphocytes on day 29 (109/L) | 0.49 (range, 0 to 5.87)* |
| Outcome | |
| Alive | 86 (43%)-151 |
| Relapse | 25 (12%)-151 |
| Toxic deaths | 92 (46%) |
*Excluding 9 patients who died before day 29. Lymphocyte counts were not available for 4 patients who were alive on day 29.
Two relapsing patients are alive in remission after donor leukocyte infusions.